Radiation With or Without 6 Months of Androgen Suppression Therapy in Intermediate- and High-Risk Clinically Localized Prostate Cancer: A Postrandomization Analysis by Risk GroupPage 1046
P. L. Nguyen, M.-H. Chen, C. J. Beard, W. W. Suh, A. A. Renshaw, M. Loffredo, E. Mcmahon, P. W. Kantoff, and A. V. D'amico
The DFCI 95-096 randomized trial demonstrated that the addition of 6 months of androgen deprivation therapy (ADT) to 70Gy of radiation improves overall survival for patients with unfavorable localized prostate cancer. While it is often supposed that the benefit was only in the high-risk subgroup, this post-randomization analysis suggests that both intermediate-risk and high-risk patients experienced a similar relative reduction in the risk of death. However, the absolute benefit was larger among high-risk patients than among intermediate-risk patients, and no benefit was seen in men with moderate or severe comorbidities.
Pathologic Nodal Classification is the Most Discriminating Prognostic Factor For Disease-free Survival in Rectal Cancer Patients Treated With Preoperative Chemoradiotherapy and Curative ResectionPage 1158
T.H. Kim, H.J Chang, D. Y. Kim, K. H. Jung, Y. S. Hong, S. Y. Kim, J. W. Park, J. H. Oh, S.-B lim, H. S. Choi, and S.-Y. Jeong
This study evaluated clinical and pathologic factors predicting disease-free survival (DFS) in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and curative resection. Four tumor response-related pathologic factors, ypT, ypN, ypStage, and tumor regression grade, were of significant prognostic value in predicting DFS. Among these factors, ypN showed the strongest discrimination for DFS prediction, followed by ypStage, ypT, and tumor regression grade, in that order. This indicates the stratification of patients according to those factors in future trials may help to identify high-risk subgroups of patients who could benefit from adjuvant chemotherapy.
Combined Tlr2 and Tlr4 Deficiency Increases Radiation-Induced Pulmonary Fibrosis in MicePage 1198
A. Paun, J. Fox, V. Balloy, M. Chignard, S.T. Qureshi, and C. K. Haston
Toll like receptors can detect damaged or injured tissue and their engagement triggers an innate immune response. In this work we show that mice genetically deficient in both toll like receptors 2 & 4, but not either alone, develop enhanced radiation-induced pulmonary fibrosis. Our findings thus implicate particular innate immunity pathways in sparing the normal tissue response to radiation of the lung.
Stability, Visibility, and Histologic Analysis of a New Implanted Fiducial for use as a Kilovoltage Radiographic or Radioactive Marker for Patient Positioning and Monitoring in RadiotherapyPage 1240
D. Neustadter, M. Tune, A. Zaretsky, R. Shofti, A. Kushnir, T. Harel, D. Carmi-Yinon, and B. Corn
This article describes the Tracer (Navotek, Yokneam, Israel), a novel radiographic and/or radioactive fiducial marker for use in patient positioning and monitoring in radiation therapy. The radioactive Tracer can be tracked in realtime by the RealEye tracking system (Navotek) for fast objective patient positioning and monitoring during treatment. The Tracer is designed for enhanced stability, reduced image artifacts (star artifacts) in CT imaging, and MRI compatibility. In animal studies, the Tracer was found to be stable in soft tissue, visible in X-ray, CT, and MRI, and to induce no clinically significant histological effects.
FULL TEXT
Page 